Journal of Clinical Oncology
Articles in this Issue
PSA-based intermediate endpoints to compare radiotherapy and radical prostatectomy for the treatment of localized prostate cancer.
366 Background: There is no validated PSA-based endpoint to compare oncological outcomes after radical prostatectomy (RP) and radiation therapy (RT). We a...
<sup>18</sup> F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing first line tyrosine kinase or checkpoint inhibitor therapy.
455 Background: Evaluating the effectiveness of systemic therapy in patients with metastatic renal cell carcinoma (mRCC) is crucial for timely treatment a...
Integrating aggressive variant prostate cancer–associated tumor suppressor genes (AVPC-TSG) status to refine prognosis and predict androgen-receptor pathway inhibitors (ARPI) response in metastatic hormone-sensitive prostate cancer (mHSPC).
243 Background: Alterations in AVPC-TSG (TP53, RB1, PTEN) are related with androgen insensitivity and aggressive disease. However, their role in mHSPC pro...
PUNCH01: Interim results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC).
767 Background: Our study was established to evaluate the efficacy and safety of IAC combined with tislelizumab and BCG as a bladder-preserving treatment...
Five-year changes in urinary function and prostate volume in patients with localized prostate cancer treated with carbon ion radiotherapy: A prospective study.
378 Background: The potential of carbon ion radiation therapy (CIRT) as a curative treatment for localized prostate cancer (PCa) has garnered attention du...
A randomized phase 3 trial of docetaxel added to ADT plus ARTA in patients with metastatic hormone-sensitive prostate cancer (Adding Docetaxel, KCSG- GU22-24).
TPS276 Background: The doublet regimen, which adds docetaxel or androgen receptor-targeted agent (ARTA) such as abiraterone, enzalutamide, or apalutamide...
Oncological benefit of avelumab maintenance therapy for advanced or metastatic urothelial carcinoma in comparison with patients with conventional chemotherapy alone era.
711 Background: The benefit of avelumab maintenance therapy for advanced or metastatic urothelial carcinoma in real world practice remains unknown. We eva...
Impact of insurance type on outcomes after radical cystectomy for bladder cancer.
679 Background: A patient’s insurance status can significantly impact their access to care, potentially altering their treatment course and outcomes. This...
Evaluating the association between bone pain and radiologic progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC).
94 Background: Previous studies have shown bone pain to be associated with worse survival in patients with metastatic castration-resistant prostate cancer...
Treatment patterns of MIBC patients not receiving radical cystectomy: Results from a real-world survey in Europe.
738 Background: Neoadjuvant chemotherapy followed by Radical cystectomy (RC) is the current standard of care for muscle invasive bladder cancer (MIBC). RC...
Downregulation of E-selectin and contributions to immune restraining in prostate cancer.
257 Background: Immune surveillance in prostate cancer (PCa) relies on leukocyte trafficking into target tissues, a process mediated by endothelial adhesi...
Prognostic and predictive genomic biomarkers in metastatic clear cell renal cell carcinoma (mccRCC): A large retrospective analysis of real-world data from a US-based clinico-genomic database (CGDB).
473 Background: The absence of validated prognostic and predictive biomarkers constitutes a significant barrier to appropriate selection among immune chec...
Treatment sequence (TS) and overall survival (OS) in patients with metastatic urothelial cancer (mUC): An observational, multicenter, real-life STATES-Bladder study.
724 Background: mUC remains of poor prognosis despite standard first-line platinum-based chemotherapy (PBC), maintenance avelumab for ptd non progressing...
Safety and efficacy of immune checkpoint inhibitor rechallenge in metastatic fumarate hydratase-deficient renal cell carcinoma: A retrospective study.
500 Background: Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare subtype of kidney cancer characterized by FH-inactivating a...
First line treatment of pancreatic metastases in metastatic renal cell carcinoma: Insights from the UK Renal Oncology Collaborative (UK ROC)—Tyrosine kinase inhibitors time to shine?
514 Background: Pancreatic metastases (PM) are a rare site of spread in metastatic renal cell carcinoma (mRCC). It has been suggested that patients with P...
Real-world treatment patterns and outcomes of novel androgen receptor axis-targeted agents in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study.
368 Background: Recently, three phase III trials have demonstrated that novel androgen receptor axis-targeted agents (ARATs) significantly improved metast...
Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy.
79 Background: Lutetium-177 Prostate-specific membrane antigen (Lu-PSMA) radioligand therapy is EMA-approved for metastatic castration resistant prostate...
Fifteen-year outcomes of external radiation with or without 6 months of neoadjuvant deprivation therapy for intermediate risk prostate cancer.
388 Background: Our aim is to retrospectively compare survival outcomes in intermediate-risk prostate cancer (IRPC) treated with external-beam radiation t...
Detection of early-stage urothelial cancers using methylation patterns in urine cell-free DNA.
687 Background: Urine cell-free DNA (ucfDNA) has the potential to improve detection and monitoring of early-stage urothelial carcinoma (UC). We previously...
Characterizing the clinical and genomic features of androgen indifferent prostate cancer.
222 Background: Androgen indifferent prostate cancer (AIPC) is increasingly common and particularly lethal. Data describing these tumors are sparse and AI...
Baseline fracture risk for prostate cancer patients initiating long-term androgen deprivation therapy.
122 Background: Androgen deprivation therapy (ADT) is essential for management of advanced prostate cancer, yet it carries risks including osteoporosis an...
Updated long-term follow-up from a phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma.
811 Background: We previously reported our multicenter phase II trial of neoadjuvant gemcitabine and split-dose cisplatin (GC) in 57 patients with high-gr...
Comprehensive bladder cancer molecular profiling and monitoring based on mutational, epigenomic, and expression data from real-world patients.
860 Background: Bladder cancer poses considerable therapeutic challenges, particularly in the context of bladder preservation strategies that aim to balan...
Non-muscle invasive bladder cancer treatment selection in an emerging treatment era: A patient preference study.
754 Background: Patients with non-muscle invasive bladder cancer (NMIBC) who become unresponsive to Bacillus Calmette-Guérin (BCG) face preference-sensiti...
Pilot study evaluating duplex sequencing of urinary DNA as a biomarker for recurrence in non-muscle invasive bladder cancer.
865 Background: The detection of tumor-associated urinary DNA (uDNA) as a biomarker for non-muscle invasive bladder cancer (NMIBC) has shown promise, but...